Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion

NCT02475317 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

84

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: Placebo
DRUG: Maralixibat
DRUG: Volixibat

Sponsor

Mirum Pharmaceuticals, Inc.